Study Comparing 2 Different Formulations of Pantoprazole in Healthy Adults.

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: October 2, 2006
Last updated: March 7, 2007
Last verified: March 2007

A study comparing 2 different investigational formulations of pantoprazole in healthy adults.

Condition Intervention Phase
Healthy Subjects
Drug: pantoprazole
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study Between the Altana Formulation of Pantoprazole Delayed-Release Granules and the Wyeth Formulation of Pantoprazole Delayed-Release Granules in Healthy Subjects.

Resource links provided by NLM:

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • To determine the bioequivalence of the Altana formulation of pantoprazole to the Wyeth formulation of pantoprazole delayed-release granules.

Secondary Outcome Measures:
  • To obtain additional safety and tolerability data concerning pantoprazole in healthy subjects and to assess the pharmacokinetics of the Altana formulation.

Study Start Date: October 2006
Estimated Study Completion Date: October 2006
Detailed Description:

open-label, single-dose, randomized, 2-period, 2-sequence, crossover, inpatient bioequivalence study


Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • Men or women aged 18 to 50 years.
  • Healthy as determined by the investigator.

Exclusion Criteria

  • History or active presence of clinically important medical disease.
  • History of drug or alcohol abuse.
  Contacts and Locations
Please refer to this study by its identifier: NCT00383916

Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided Identifier: NCT00383916     History of Changes
Other Study ID Numbers: 3001B1-119
Study First Received: October 2, 2006
Last Updated: March 7, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Additional relevant MeSH terms:
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses processed this record on April 17, 2014